Roche Achieves 43.1% Proteinuria Reduction with Sefaxersen in Phase III IgA Nephropathy Trial

A 43.1% reduction in proteinuria from a single Phase III readout positions Roche's sefaxersen as a near-term regulatory submission candidate for IgA nephropathy, a rare kidney disease with limited approved therapeutic options. For regulatory affairs leads tracking oligonucleotide-class biologics, the dataset signals an accelerating path toward a Breakthrough Therapy or similar expedited designation filing.

The Phase III trial demonstrated that sefaxersen, an investigational oligonucleotide therapy, delivered statistically significant proteinuria reduction versus placebo at the primary endpoint. The trial also recorded a higher proportion of patients with haematuria at baseline achieving resolution by Week 37 with sefaxersen compared to placebo, strengthening the composite clinical picture regulators will evaluate across both endpoints.

For manufacturing and supply chain leads, sefaxersen's oligonucleotide classification carries distinct process implications. Oligonucleotide synthesis operates outside conventional small-molecule or biologics GMP frameworks, requiring solid-phase synthesis suites, specialised purification trains, and analytical methods aligned with ICH Q6B characterisation expectations. Scale-up from clinical to commercial batch sizes introduces yield and impurity-profile risks that process validation programmes must address before any pre-approval inspection.

Roche has not disclosed a regulatory submission timeline or a commercial manufacturing partner as of the trial readout. QA directors and regulatory leads at contract development and manufacturing organisations with oligonucleotide capability should monitor Roche's subsequent filings closely, as CMC package requirements for this modality remain an area of active agency scrutiny under 21 CFR Part 211 and equivalent EMA guidance.

The haematuria resolution data at Week 37 will serve as a measurable secondary endpoint benchmark when Roche's submission dossier enters agency review.

Source: Indian Pharma Post via Media4Growth, 26 October 2026.